FY2026 – NicoNico News

The news regarding ‘FY2026’ suggests an impending simultaneous revision of medical fees and long-term care fees, which will be a critical turning point for healthcare institution management. This large-scale revision is expected to significantly impact the revenue structure and future prospects of healthcare institutions, thus directly affecting business succession and M&A strategies for medical corporations. In particular, early consideration with an eye on the revision details and strategy formulation based on expert knowledge will be indispensable.

Impact of the FY2026 Simultaneous Revision on M&A Valuation of Healthcare Institutions

The period of ‘FY2026’ holds significant meaning for healthcare institution managers. This year, a simultaneous revision of medical fees and long-term care fees is scheduled, which is certain to have a major impact on the entire healthcare delivery system. Specifically, policy guidance such as the differentiation and reorganization of bed functions linked to the advancement of regional medical care visions, clarification of outpatient functions, and strengthening of home medical care and long-term care collaboration are presumed to significantly influence the revenue structure and future business viability of healthcare institutions.

The valuation of healthcare institutions in M&A considers not only past financial performance but also future profitability and growth potential, regional necessity, and compliance with facility standards. The FY2026 revision will directly impact the attractiveness of healthcare institutions as M&A targets and the criteria for calculating transfer prices, as revenue sources for institutions with specific departments or functions may change, or new facility standards may be required. For example, revisions to basic inpatient fees and specified inpatient fees could fundamentally alter the management of medical corporations with hospital beds, potentially leading to significant fluctuations in enterprise valuation.

Importance of Early Medical Business Succession and M&A Consideration in Anticipation of the Revision

Amidst such a large-scale revision, chairpersons and hospital directors considering business succession or M&A must undertake early and strategic preparation. The ‘value of early consideration,’ as highlighted in the news summary, precisely refers to an M&A strategy that incorporates this revision risk. Before the revision details are finalized, it is necessary to conduct a multifaceted analysis of one’s institution’s strengths and weaknesses, its positioning in the region, and future policy trends, to determine which succession scheme (e.g., transfer of equity interests, business transfer, corporate merger) is optimal.

Generally, M&A preparation is said to take about 5 to 10 years, but in anticipation of a major wave like the FY2026 revision, starting consideration around age 60 is ideal. Especially for medical corporations with equity interests, post-revision revenue forecasts significantly impact valuation, making timely sale decisions crucial. Before post-revision uncertainties increase, it is necessary to formulate a concrete action plan to bridge the gap between one’s ideal succession vision and market valuation.

Significance of Utilizing Expert Advisors in a Complexifying Environment

Medical M&A surrounding the FY2026 revision faces a complex phase that demands a deep understanding of the entire healthcare system, extending beyond mere financial analysis. The ‘engagement of expert advisors,’ as indicated in the news summary, can be considered an essential requirement for navigating this complexity.

Support organizations specializing in medical M&A possess expert knowledge regarding trends in medical fee revisions, consistency with regional medical plans, interpretation of facility standards, and legal/tax matters specific to medical corporations (e.g., change of members/directors, transition to endowment-type medical corporations, capital gains tax). This expertise is extremely important for evaluating the feasibility of post-revision business plans and for setting appropriate prices during negotiations with potential buyers. Furthermore, by identifying potential risks and constructing the optimal M&A structure, they serve as a compass for achieving smooth and successful succession for both sellers and buyers.

If you are specifically considering business succession or M&A for a medical corporation or clinic, please utilize our free preliminary assessment or individual consultation (strict confidentiality, fully success-fee based).